Biocon Biologics’ Yesafili (biosimilar, aflibercept) Receives EC’s Approval for Ophthalmic Conditions
- The EC has granted marketing authorization for Yesafili, a biosimilar of Aflibercept for the treatment of patients with age-related macular degeneration and diabetic macular edema
- Yesafili is intended for the treatment of neovascular (wet AMD), visual impairment due to macular oedema secondary to RVO, visual impairment due to DME, and myopic CNV
- Yesafili was highly similar to the reference aflibercept & the results showed that Yesafili has comparable quality, safety, and efficacy to Eylea. The centralized marketing authorization is valid in all EU Member States, EEA countries Iceland, Liechtenstein, and Norway
Ref: Biocon Biologics | Image: Biocon Biologics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.